In addition to O James Sterling, 2 other RTNXF executives reported Sell trades in the last month.
Based on Renalytix AI’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $619K and GAAP net loss of -$8,776,000. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $731K. The company has a one-year high of $17.15 and a one-year low of $5.35. Currently, Renalytix AI has an average volume of 458.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.